Melanoma Metabolism: Cell Survival and Resistance to Therapy
Authors:
- 5 March 2020
- book chapter
- Published by Springer Nature
- Vol. 1219, 203-223
Abstract
Cutaneous melanoma is one of the most aggressive types of cancer, presenting the highest potential to form metastases, both locally and distally, which are associated with high death rates of melanoma patients. A high somatic mutation burden is characteristic of these tumours, with most common oncogenic mutations occurring in the BRAF, NRAS and NF1 genes. These intrinsic oncogenic pathways contribute to the metabolic switch between glycolysis and oxidative phosphorylation metabolisms of melanoma, facilitating tumour progression and resulting in a high plasticity and adaptability to unfavourable conditions. Moreover, melanoma microenvironment can influence its own metabolism and reprogram several immune cell subset functions, enabling melanoma to evade the immune system. The knowledge of the biology, molecular alterations and microenvironment of melanoma has led to the development of new targeted therapies and the improvement of patient care. In this work, we reviewed the impact of melanoma metabolism in the resistance to BRAF and MEK inhibitors and immunotherapies, emphasizing the requirement to evaluate metabolic alterations upon development of novel therapeutic approaches. Here we summarized the current understanding of the impact of metabolic processes in melanomagenesis, metastasis and microenvironment, as well as the involvement of metabolic pathways in the immune modulation and resistance to targeted and immunocheckpoint therapies.Keywords
This publication has 142 references indexed in Scilit:
- PI3Kα activates integrin α4β1 to establish a metastatic niche in lymph nodesProceedings of the National Academy of Sciences, 2013
- A Landscape of Driver Mutations in MelanomaCell, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- Comparative Metabolic Flux Profiling of Melanoma Cell LinesJournal of Biological Chemistry, 2011
- Melanoma in adolescents and young adults (ages 15-39 years): United States, 1999-2006Journal of the American Academy of Dermatology, 2011
- Adenosine promotes alternative macrophage activation via A2A and A2B receptorsThe FASEB Journal, 2011
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensationTrends in Biochemical Sciences, 2011
- The integrin–actin connection, an eternal love affairThe EMBO Journal, 2003
- Tumour-cell invasion and migration: diversity and escape mechanismsNature Reviews Cancer, 2003
- Mutations of the BRAF gene in human cancerNature, 2002